KR910015297A - 오메프라졸 경구용 약제와 그 제조방법 - Google Patents

오메프라졸 경구용 약제와 그 제조방법 Download PDF

Info

Publication number
KR910015297A
KR910015297A KR1019900002010A KR900002010A KR910015297A KR 910015297 A KR910015297 A KR 910015297A KR 1019900002010 A KR1019900002010 A KR 1019900002010A KR 900002010 A KR900002010 A KR 900002010A KR 910015297 A KR910015297 A KR 910015297A
Authority
KR
South Korea
Prior art keywords
oral
omeprazole
medicament
water
amino acid
Prior art date
Application number
KR1019900002010A
Other languages
English (en)
Other versions
KR920008161B1 (ko
Inventor
김광식
Original Assignee
임성기
한미약품공업 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임성기, 한미약품공업 주식회사 filed Critical 임성기
Priority to KR1019900002010A priority Critical patent/KR920008161B1/ko
Publication of KR910015297A publication Critical patent/KR910015297A/ko
Application granted granted Critical
Publication of KR920008161B1 publication Critical patent/KR920008161B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

오메프라졸 경구용 약제와 그 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 오메프라졸을 유효성분으로 하는 장용성 경구용 약제에 있어서, 코어물질의 안정화제로서 수용성 염기성아미노산을 함유하고 있는 것을 특징으로 하는 오메프라졸 경구용 약제.
  2. 제1항에 있어서, 상기 수용성염기성 아미노산은 아르리닌, 리진 또는 히스티딘인 것을 특징으로 하는 오메프로졸 경구용 약제.
  3. 제1항 또는 제2항에 있어서, 상기 수용성염기성 아미노산은 상기 오메프라졸 1몰에 대해 0.1 내지 5몰이 함유되어 있는 것을 특징으로 하는 오메프라졸 경구용 악제.
  4. 제1항에 있어서, 상기 약제에는 상용되고 있는 유당이 함유되어있지 않은 것을 특징으로 하는 오메프라졸 경구용 약제.
  5. 오메프라졸을 유효성분으로 함유하는 장용성경구용 약제를 제조함에 있어서, 코어물질의 안정화제로서 수용성 염기성아미노산을 상기 오메프라졸 1몰에 대해 0.1 내지 5몰로 사용하여서 제조됨을 특징으로 하는 오메프라졸 경구용 약제의 제조방법.
  6. 제5항에 있어서, 상기 약제는 그 약제중에 함유되는 코어물질을 안정화시키기 위해 수용성폴리머로 1차피복시킨후, 장용성피복물질로 2차 피복시켜서 안정화된 장용성제제로 제조함을 특징으로 하는 오메프라졸 경구용 약제의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019900002010A 1990-02-19 1990-02-19 오메프라졸 경구용 약제의 제조방법 KR920008161B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019900002010A KR920008161B1 (ko) 1990-02-19 1990-02-19 오메프라졸 경구용 약제의 제조방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019900002010A KR920008161B1 (ko) 1990-02-19 1990-02-19 오메프라졸 경구용 약제의 제조방법

Publications (2)

Publication Number Publication Date
KR910015297A true KR910015297A (ko) 1991-09-30
KR920008161B1 KR920008161B1 (ko) 1992-09-24

Family

ID=19296183

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900002010A KR920008161B1 (ko) 1990-02-19 1990-02-19 오메프라졸 경구용 약제의 제조방법

Country Status (1)

Country Link
KR (1) KR920008161B1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100408582B1 (ko) * 1994-12-10 2004-03-04 론-폴렝 로레르 게엠베하 경구투여용약제학적조성물

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131651A0 (en) * 1997-03-13 2001-01-28 Hexal Ag A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100408582B1 (ko) * 1994-12-10 2004-03-04 론-폴렝 로레르 게엠베하 경구투여용약제학적조성물

Also Published As

Publication number Publication date
KR920008161B1 (ko) 1992-09-24

Similar Documents

Publication Publication Date Title
KR840000228A (ko) 조제성 혼합물에 있어서 건성분말의 제조방법
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
DE69840495D1 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
DE69633018D1 (de) Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
ATE353009T1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
IE891919L (en) Pharmaceutical dosage form for the medication of fish
SE8300577D0 (sv) Overdrag som tillforsekrar reglerad avgivning av akriva bestandsdelar fran biologiskt aktiva blandningar, i synnerhet farmaceutiska beredningar, jemte sett att framstella biologiskt aktiva blandningar med reglerad ....
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
SE8804628D0 (sv) New compounds
GB2181646A (en) Medicated chewing gum
DK0460622T3 (da) Lægemiddelpræparat til systemisk behandling af pryd- og nyttefisk
ATA379182A (de) Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
FI962056A0 (fi) Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan
GB2328872B (en) Method for preparing pharmaceutical formulations
KR910015297A (ko) 오메프라졸 경구용 약제와 그 제조방법
EP0271151A3 (en) Azumolene dosage form
KR900015732A (ko) 경구용 제제
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
KR900017599A (ko) 종양 치료용 약학 조성물
DE59007260D1 (de) Pharmazeutische zubereitung zur rektalen verabreichung.
KR880002537A (ko) 생약제제
KR900701263A (ko) 이보파민의 수용성 산 부가 염을 포함하는 안과용 약학 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
O035 Opposition [patent]: request for opposition
E701 Decision to grant or registration of patent right
O073 Decision to grant registration after opposition [patent]: decision to grant registration
GRNT Written decision to grant
J204 Request for invalidation trial [patent]
J2X1 Appeal (before the patent court)

Free format text: INVALIDATION IN ENTIRETY

Free format text: TRIAL NUMBER: 1998200002092; INVALIDATION IN ENTIRETY

Free format text: TRIAL NUMBER: 1997200000321; INVALIDATION IN ENTIRETY

J121 Written withdrawal of request for trial
J122 Written withdrawal of action (patent court)
FPAY Annual fee payment

Payment date: 20090701

Year of fee payment: 18

EXPY Expiration of term